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Background
AV Fistula (AVF) maturation delay impacts its functional patency and prolongs
catheter dependence. USRDS (2015) reports median time to first cannulation
of 112 days and only 45% of AVF are suitable for dialysis at 6 months [Range
38% (DAC) to 65% (HFM)]. A prior single arm Phase 2 study (Table) tested the
value of perivascular sirolimus delivered intraoperatively at and around the AVF
anastomosis from a collagen membrane (drug product; Vascular Therapies,
Cresskill, NJ), for improving AVF outcomes.
Methods
Incident ESRD patients undergoing hemodialysis via catheter at time of AVF
creation [Radiocephalic (RCF) or Brachiocephalic (BCF)] are eligible for
enrollment in this ongoing US Phase 3 multicenter, randomized controlled
clinical trial (NCT02513303). The first subject enrolled at each site received the
drug product [“Open label” subject, (OL)]. Baseline vascular mapping
(cephalic vein ≥2.5 mm; artery ≥2 mm; vein depth ≤5 mm) was performed to
ensure suitability.
Results
There were no product related serious adverse events. Table lists key demographic and
outcome metrics. Time to First Dialysis (TTFD): Time from AVF creation, to the time when the
fistula can support three consecutive 2 needle dialysis sessions with a mean dialysis pump flow
of ≥300 mL/min (2N/300). Fistula Suitability for Dialysis at 6 months (FSD6): Ability to use the
fistula (2N/300) for two thirds of the dialysis sessions during a 30 day suitability ascertainment
period commencing on day 150.
Excluding the 2 AVF that thrombosed early, TTFD was <90 days for 11/16 (69%) subjects.
Conclusion
1. Time to maturation and AVF suitability for dialysis at 6 months in the open label Phase 3
subjects are similar to Phase 2 results and signal an improvement in comparison to historical
controls.
2. Results are promising and may suggest that prophylactic local treatment with sirolimus at
time of AVF creation could predictably reduce catheter dependence to less than 90 days
with durable AV fistula functionality.
Enrollment is ongoing in the ACCESS trial.
Phase N Age (y)Mean (range) Male Diabetes RCF BCF Thrombosis*
TTFD (d)
Median (range)** FSD6










* Within 2 weeks of surgery ** Excludes  thrombosis prior to first cannulation
